Controlling Health Care Costs Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier? Issue Briefs / Oct 05, 2017
Controlling Health Care Costs The Case for Drug-Pricing Reform — The Cost of Inaction blog / May 26, 2021
Controlling Health Care Costs External Reference Pricing: The Drug-Pricing Reform America Needs? Issue Briefs / May 27, 2021
Controlling Health Care Costs How Federal Drug-Pricing Proposals Could Affect Medicaid blog / Aug 19, 2021
Controlling Health Care Costs Reducing Medicaid Prescription Drug Costs While Maintaining Beneficiary Access: MACPAC Recommendations for Accelerated-Approval Drugs blog / Aug 18, 2021
Controlling Health Care Costs Can State Prescription Drug Affordability Boards Address High-Cost Drug Prices? Blog / Oct 11, 2022
Controlling Health Care Costs What the Inflation Reduction Act Really Means for Health Care Podcast / Sep 09, 2022
Controlling Health Care Costs The Federal 340B Drug Pricing Program: What It Is, and Why It’s Facing Legal Challenges Explainer / Sep 08, 2022
Controlling Health Care Costs The Inflation Reduction Act is a Milestone Achievement in Lowering Americans’ Health Care Costs Blog / Aug 15, 2022
Controlling Health Care Costs The Impact of Pharmaceutical Wholesalers on U.S. Drug Spending Issue Briefs / Jul 20, 2022
Controlling Health Care Costs The Accelerated Approval Pathway for New Drug Therapies: Controversies and Proposed Fixes Explainer / Jul 14, 2022
Advancing Health Equity Disparities in the Use of New Diabetes Medications: Widening Treatment Inequality by Race and Insurance Coverage Issue Briefs / Jun 14, 2022
Controlling Health Care Costs Public Good vs. Private Gain: The Role of Public–Private Partnerships in Drug Innovation and Pricing Blog / Jun 08, 2022
Controlling Health Care Costs A Value-Based Approach to America’s Costly Prescription Drug Problem Blog / May 06, 2022
Controlling Health Care Costs Are Pharmacy Benefit Managers the Next Target for Prescription Drug Reform? Blog / Apr 20, 2022